Vector Science Starts Manufacturing Pharma-Grade Peptides

10:57 AM EDT, 08/24/2026 (MT Newswires) -- Vector Science & Therapeutics (PAIN.V) said Monday that the first of four planned manufacturing suites at its LyoGenesis Manufacturing facility in Wisconsis is now producing pharma-grade peptides. The first suite can produce 55,000 vials per month, which has been presold, a statement said. The three remaining LyoGenesis Manufacturing suites will come online in the second half of next month. Outside of GLP-1, which manages type 2 diabetes and aids in weight loss, Vector will focus production on top-selling peptides and complementary compounds to meet growing demand for peptides in the US. Vector expects to retain an 80% margin on each sale. The company's shares were last seen up C$0.05, to C$1.88, on the TSX Venture Exchange. Price: 1.88, Change: +0.05, Percent Change: +2.73